Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 87
- Registration Number
- NCT00200967
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸National Jewish Medical & Research Center, Denver, Colorado, United States
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 740
- Registration Number
- NCT00144911
- Locations
- 🇨🇦
GSK Investigational Site, Sorel, Quebec, Canada
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
- Conditions
- Exercise Induced Asthma
- Interventions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 154
- Registration Number
- NCT00127166
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 797
- Registration Number
- NCT00115492
- Locations
- 🇨🇦
GSK Investigational Site, Trois Rivieres, Quebec, Canada
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
- Conditions
- Asthma
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 547
- Registration Number
- NCT00102882
- Locations
- 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary DiseaseChronic BronchitisEmphysema
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 741
- Registration Number
- NCT00064402
- Locations
- 🇺🇸
Advances in Medicine, Rancho Mirage, California, United States
🇺🇸Office of Bradley Sakran, MD, PC, O'Fallon, Illinois, United States
🇺🇸University of Maryland-Airways Research Center, Baltimore, Maryland, United States
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
- Conditions
- Chronic Obstructive Pulmonary DiseaseChronic BronchitisEmphysema
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 799
- Registration Number
- NCT00064415
- Locations
- 🇺🇸
Advances in Medicine, Rancho Mirage, California, United States
🇺🇸Inland Clinical Research, Inc., Riverside, California, United States
🇺🇸New Horizon Health Research, Atlanta, Georgia, United States
A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2000-04-14
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00005110
- Locations
- 🇺🇸
Division of Allergy and Pulmonary Medicine, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.